Phase II trials of bortezomib (PS-341, Velcade™), a selective proteasome inhibitor, in non-Hodgkin's lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL LYMPHOMA | 2003年 / 4卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 82
页数：4
相关论文
共 50 条
  • [1] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
  • [2] Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
    Shah, MH
    Young, D
    Kindler, HL
    Webb, I
    Kleiber, B
    Wright, J
    Grever, M
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6111 - 6118
  • [3] A phase 8 and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib ,velcade), in patients with advanced cancer
    Dy, GK
    Thomas, JP
    Wilding, G
    Bruzek, L
    Mandrekar, S
    Erlichman, C
    Alberti, D
    Binger, K
    Pitot, HC
    Alberts, SR
    Hanson, LJ
    Marnocha, R
    Tutsch, K
    Kaufmann, SH
    Adjei, AA
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3410 - 3416
  • [4] A phase II trial of the proteosome inhibitor PS-341 (Bortezomib; Velcade)in patients with metastatic colorectal cancer.
    Mackay, HJ
    Major, P
    Townsley, C
    Mackenzie, M
    Vincent, M
    Boudreau, T
    Tsao, M
    Hedley, D
    Wright, J
    Siu, L
    Moore, M
    Oza, AM
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6201S - 6201S
  • [5] The proteasome inhibitor PS-341 (Velcade®) in the treatment of pancreatic carcinoma.: Critical discussion of a phase II study
    Arit, Alexander
    Foelsch, Ulrich R.
    [J]. MEDIZINISCHE KLINIK, 2006, 101 (08) : 668 - 670
  • [6] Current clinical trials for the proteasome inhibitor PS-341
    不详
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (11): : 1589 - +
  • [7] Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
    Serra Kamer
    Qing Ren
    Adam P. Dicker
    [J]. Archives of Gynecology and Obstetrics, 2009, 279 : 41 - 46
  • [8] Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects
    Shahshahan, Mohammad A.
    Beckley, Maureen N.
    Jazirehi, Ali R.
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2011, 1 (07): : 913 - 924
  • [9] Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
    Kamer, Serra
    Ren, Qing
    Dicker, Adam P.
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2009, 279 (01) : 41 - 46
  • [10] Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Mack, PC
    Davies, AM
    Lara, PN
    Gumerlock, PH
    Gandara, DR
    [J]. LUNG CANCER, 2003, 41 : S89 - S96
12345